Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2015 | FIRST trial: Continuous lenalidomide plus dexamethasone for newly diagnosed multiple myeloma

Thierry Facon • 11 Jun 2015
EHA 2015
Multiple Myeloma Lenalidomide

At the 20th Congress of the European Hematology Association (EHA), Thierry Facon, MD, of the University Hospital Hurriez, Lille, France, discusses the updated overall survival analysis of the FIRST study, which compared treatment with continuous lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, and thalidomide (MPT) in patients with newly diagnosed multiple myeloma.

More from Thierry Facon

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma 3:57
IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myeloma
Thierry Facon • 14 Jun 2024
Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates 5:09
Myeloma: MAIA, COLUMBA, and CASSIOPEIA updates
Thierry Facon • 14 Jun 2019
Upcoming updates in multiple myeloma 3:23
Upcoming updates in multiple myeloma
Thierry Facon • 14 Jun 2019
2:19
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon • 11 Dec 2018

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals